Latest News

Freshpet's marketing bet is tilted toward its most valuable households, which the article says make up 72% of sales, so the company is protecting that base.

A single confirmatory Phase III trial design could streamline the path to regulatory approval if November data validates the oligomer-targeting approach.

Retailer restocking after cyberattacks turned temporary outages into a sales boost, while closing a factory targets overhead rather than shelf prices.

TikTok Shops in 14 countries now feed sales into major retailers and direct-to-consumer sites, reaching beyond traditional channels.

Large deal wins provide multiyear revenue visibility even as near-term pricing pressure forces guidance cuts.

Intuit took steps to embrace AI.

The bank's willingness to sacrifice market share for loan pricing power signals how disciplined management can sustain profitability across rate cycles.

Brookfield Infrastructure's growing cash earnings support its payout, with financing costs setting the pace of the next increase.

A rival chipmaker is buying a big laser maker. Is the AI chip giant's stock, around 30% under its record, still worth buying?

Gross margin climbed to 22.5% in the first half, and management expects further gains, pointing to better profit quality beyond sheer deal volume.

Investors were clearly impressed by the gaming company's third-quarter performance.

See why Canadian Natural Resources and CN Rail deserve a spot in a buy and hold dividend portfolio built to last for years.

The education company's patience is paying off.

Is the AI boom running out of steam, or is the market simply taking a breather?

Telus and BCE now offer similar starting yields, making payout coverage and recovery demands the more useful comparison.

GRAIL (NASDAQ:GRAL) reported 4% revenue growth for the third quarter of 2026 as higher testing volumes were offset in part by lower prices, and said it expects a U.S. regulatory decision on its Galleri cancer screening test by early in the first quarter of 2027. The company reported revenue of $37.

ARM (NASDAQ:ARM) reported record second-quarter fiscal 2027 revenue as licensing demand and data center royalties grew, while executives said they had greater confidence in the sales potential of the company’s forthcoming Arm AGI CPU. Revenue rose 27% year over year to $1.44 billion, marking Arm’s

electroCore (NASDAQ:ECOR) reported record third-quarter sales and a narrower loss, but revised its 2026 revenue outlook as changes to its sales organization took longer than expected to reach the full field. The medical device company reported revenue of $9.7 million for the quarter ended Sept. 30,

Caris Life Sciences (NASDAQ:CAI) raised its full-year revenue outlook after third-quarter sales rose 27%, as growth in cancer-testing volumes accelerated for a second consecutive quarter. The company also reported lower quarterly profit as it increased spending on its sales force, marketing and new

Amplitude (NASDAQ:AMPL) reported third-quarter revenue of $111 million, up 25% from a year earlier, and raised its full-year outlook as enterprise customers adopted more of its analytics and experimentation products. The company recorded non-GAAP operating income of $5.7 million, its highest quarte

Barrett Business Services (NASDAQ:BBSI) reported higher third-quarter gross billings but lower earnings per share as new client additions were offset by workforce reductions among existing customers and smaller favorable workers’ compensation adjustments. The company lowered its full-year outlook f

Expedia Group (NASDAQ:EXPE) raised its full-year 2026 outlook after third-quarter bookings and revenue grew by double digits, though executives expect growth to moderate in the fourth quarter as travel disruptions, tougher comparisons and the timing of a promotion weigh on results. Gross bookings r

ACADIA Pharmaceuticals (NASDAQ:ACAD) reported third-quarter 2026 revenue of $342 million, up 22% from a year earlier on an adjusted basis, as demand for its Rett syndrome treatment DAYBUE and Parkinson’s disease psychosis drug NUPLAZID drove growth. The company raised its full-year DAYBUE sales out

Clover Health Investments (NASDAQ:CLOV) raised the lower end of its 2026 financial guidance after reporting a third-quarter profit, and said it expects to achieve its first full year of GAAP net income profitability. The Medicare Advantage insurer reported third-quarter revenue of $759 million, up

Beyond Meat (NASDAQ:BYND) reported a narrower third-quarter loss and its highest gross margin in five years, but revenue continued to fall as weaker U.S. demand and lower international food-service sales outweighed growth in international retail. The plant-based food company reported revenue of $64